Promethera Biosciences

Promethera Biosciences Appoints Mutsuki Takano to Group Chief Financial Officer

Mont-Saint-Guibert, Belgium, October 5th, 2018 – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that Mutsuki Takano, currently Branch General Manager of Promethera Biosciences Japan Branch and Member of the Management Team of Promethera Biosciences SA will succeed Frank Hazevoets as Group Chief Financial Officer (Group CFO), in addition to his current responsibilities. 

Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases

Funding Used to Advance Clinical Pipeline and Strengthen Product Portfolio

Mont-Saint-Guibert, Belgium, April 10, 2018 – Promethera Biosciences SA a global innovator in cell-based medicines and liver diseases, today announced that it raised EUR 9.3 million (approx. USD 11.5 million) through the issuance of convertible bonds to existing and new investors. Major existing shareholders renewed their commitment and participated in the convertible bonds issued.

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Transaction Underpins Promethera’s Commitment to Become the Leading Drug Developer in Severe Liver Diseases 

Mont-Saint-Guibert, Belgium, and Basel, Switzerland, April 10, 2018 – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that it has acquired Baliopharm AG, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseases and cancer.

Promethera Biosciences Announces Updates to its Board of Directors Charles L. Dimmler, III elected as new Chairman of the Board

Mont-Saint-Guibert, Belgium, April 6, 2018 – Promethera Biosciences SA, a global innovator in cell-based medicines, today announced the following changes to its Board of Directors. Mr Charles L.

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Poster at EASL Annual Congress 2018 Confirms HepaStem’s Anti-inflammatory Effect and Potential to Reduce Fibrosis in a Proven NASH Model

Mont-Saint-Guibert, Belgium, April 5, 2018 – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that the Company will participate in two upcoming scientific and partnering conferences in Europe and the US.

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Mont-Saint-Guibert, Belgium, and Kanazawa, Ishikawa, Japan October 5, 2017 –Promethera Biosciences SA, a global innovator in cell-based medicines, and Shibuya Corporation (6340:Tokyo Stock Exchange) announced today a strategic collaboration to establish a high-throughput, commercial-scale and clinical-grade cell therapy and regenerative medicine manufacturing platform.

Sign Up